Objectives: Pharmacodynamics of b-lactamase inhibitors are an area of intense interest as new b-lactam/b-lactamase inhibitor combinations enter clinical development and clinical practice. Avibactam, a non-b-lactam b-lactamase inhibitor, has been combined with ceftaroline or ceftazidime but these two combinations have not been directly compared.
Introduction
Avibactam is a non-b-lactam b-lactamase inhibitor that inhibits Class A and Class C b-lactamases and, as such, it restores the susceptibility to ceftaroline and ceftazidime of Enterobacteriaceae with ESBLs, AmpC, KPC and OXA-48 carbapenemases but not for those with metallo-b-lactamases. 1, 2 Avibactam has been combined with ceftaroline, ceftazidime or aztreonam in antibiotic development. Ceftazidime/avibactam has completed Phase 3 clinical trials and has been approved (2015) for clinical use in the USA and Europe while aztreonam/avibactam is planned to enter Phase 2 trials soon. A single Phase 2 study has been conducted on ceftaroline/avibactam in complicated urinary tract infections but there has been no further clinical development.
Ceftaroline/avibactam and ceftazidime/avibactam have been evaluated in pre-clinical pharmacokinetic (PK) models of infection 3, 4 but thus far, they have not been directly compared. 3, 5 Our objective was to try performing dose escalation and fractionation studies with avibactam in combination with exposures representative of standard doses of ceftaroline or ceftazidime in patients to determine the dominant PK driver of avibactam's inhibitory activity in an in vitro continuous culture model. In addition, we sought to compare the activities of ceftaroline and ceftazidime combined with avibactam.
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Materials and methods

In vitro PK model
A Fermac 301 Fermentation System (Electrolab, Tewkesbury, UK) in vitro PK model was used to simulate free drug concentrations of ceftaroline associated with dosing 600 mg intravenous (iv) every 8 h and ceftazidime 2000 mg iv every 8 h dosing. Avibactam was instilled at final concentrations of 0.5, 1, 2, 4, 6, 8 and 10 mg/L by continuous infusion in an initial series of experiments, subsequently at 24 h AUC (mgÁh/L) exposures of 1.2, 18, 24, 36 and 108 mgÁh/L doses were given as single doses or every 8 h to achieve the same 24 h AUC. Avibactam was also fractionated by dosing in the model as a single or three daily doses. For the Escherichia coli CTX-M producer, four avibactam AUC 24 exposures were tested: 1.2, 24, 36 and 72 mgÁh/ L; for the Enterobacter AmpC hyper-producer AUC 24 1.2 mg/L and 24 mg/L; and for the Klebsiella pneumoniae KPC producer avibactam AUC 24 1.2, 36, 72 and 108 mgÁh/L. The log change in viable count at 24 h (D24 log cfu/mL) for continuous infusion was taken as baseline and the differences with single exposure (24 h) and three exposures (8 h) calculated. The apparatus that has been described before consists of a single central chamber connected to a reservoir containing broth. The central chamber was connected to a vessel for overflow. The contents of the central chamber were diluted with broth using a peristaltic pump (Ismatec; Cole-Palmer, Hanwell, London, UK). The temperature was maintained at 37 C and broth in the central chamber agitated by a magnetic stirrer.
Media
One hundred per cent cation supplemented Mueller-Hinton broth (MHB) was used in all experiments. Nutrient agar plates (Oxoid, Basingstoke, UK) were used to recover bacterial strains from the model. Samples were taken by pipette from the central chamber and cultured immediately. Five microlitres b-lactamase/mL (supplied by Dr J. Spencer, University of Bristol) was used to neutralize the cephalosporins. The b-lactamase was an IMP-1 carbapenemase from E. coli.
MICs
Ceftaroline and ceftazidime MICs were determined by standard broth dilution methods according to CLSI Guidelines. 6 MICs were determined in 100% MHB in a non-doubling dilution to determine more accurately the MICs in the presence of 4 mg/L fixed concentration avibactam.
Strains
Three strains of Enterobacteriaceae were studied: E. coli SMD 35756 CTX-M producer (ceftaroline MIC 0.12 mg/L, ceftazidime MIC 0.38 mg/L); E. cloacae SMD 42424 AmpC producer (ceftaroline MIC 1.8 mg/L, ceftazidime MIC 0.5 mg/L), K. pneumoniae SMD 42421 KPC producer (ceftaroline MIC 2.0 mg/L, ceftazidime MIC 4.5 mg/L). The E. cloacae and K. pneumoniae strains were kindly supplied by Dr R. Jones, JMI Laboratories (North Liberty, IA, USA).
Antibiotics
Ceftaroline and avibactam were supplied by Cerexa (Oakland, CA, USA). Ceftazidime was supplied by Wockhardt (Wrexham, UK). Fresh solutions were prepared according to BSAC Guidelines. 7 
PKs
Free drug concentration of ceftaroline 600 mg every 8 h were modelled with single-compartment kinetics-C max 27.1 mg/L, t1 =2 2.5 h and ceftazidime 2000 mg every 8 h by 2 h infusion also modelled with singlecompartment kinetics-C max 46.3 mg/L t1 =2 2 h. As the half-lives and infusion rates of ceftaroline and ceftazidime were slightly different, the shapes of the avibactam exposures were also slightly different comparing the ceftaroline and ceftazidime avibactam exposures. The avibactam 24 h AUC is 159 mgÁh/L for 600 mg, avibactam every 8 h, which is equivalent to a continuous infusion concentration of 6.6 mg/L over 24 h. Ceftaroline and ceftazidime concentrations were confirmed by HPLC. Ceftaroline chromatography was performed using a Gemini NXNM C18110A column (Phenomenex, Macclesfield, UK). The mobile phase comprised 0.1 M sodium acetate/0.1 M glacial acetic acid/acetonitrile 86:28:11.2 v/v and wavelength 254 nm. The flow rate was 1.8 mL/min. Detection was by UV absorbance. Ceftazidime was separated using a Hypersil 5 ODS column. The mobile phase comprised methanol, H 2 O and phosphoric acid in 25:74:1 v/v. Wavelength was 254 nm, detection was by UV absorbance and flow rate was 1 mL/min. Avibactam concentrations were quality assured using flucytosine as the surrogate. A flucytosine simulation was performed in parallel with the avibactam simulations.
Antibacterial effects
Experiments were performed at an initial inoculum of 10 6 cfu/mL. Samples were taken throughout the sampling period up to 72 h for quantification of viable counts. Bacteria were counted by a spiral plater (Don Whitley Systems, Shipley, West Yorkshire, UK). The minimum level of detection is 10 2 cfu/mL. Aliquots were stored at -70 C for ceftaroline and ceftazidime assay.
Measurement of antibacterial effects and pharmacodynamics (PD)
The area-under-the-bacterial-kill-curve (AUBKC log cfu/mLÁh) was calculated using the log linear-trapezoidal rule for times 0-24 h (AUBKC 24), 0-48 h (AUBKC 48) and 0-72 h (AUBKC 72). The log change in viable counts compared to initial inoculum was also determined at 24 h (D24). AUBKC and D24 was related to avibactam exposures using the Sigmoid E max Model and D24 was related to avibactam AUC, C max , T > 1 mg/L, T > 2 mg/L and T > 4 mg/L again using the Sigmoid E max model, Version 4 (Graph Pad Prism, San Diego, CA, USA).
Results
PK curves
The target and measured PK values for ceftaroline 600 mg every 8 h, ceftazidime 2000 mg every 8 h and avibactam (measured as Pharmacodynamics of avibactam plus two cephalosporins JAC surrogate) are shown in Table 1 and Figure 1 . There was good agreement between the target and observed concentrations.
Antibacterial effect of avibactam in combination with ceftaroline or ceftazidime 
Dose fractionation with avibactam
No consistent pattern emerged to suggest superiority of single or multiple drug exposures to avibactam over the 72 h of simulation when log changes in viable counts were compared with those for continuous infusion avibactam ( Table 2) .
Relationship of avibactam AUC, C max or time over predefined threshold concentration to antibacterial effect
The ceftaroline and ceftazidime data sets were analysed separately to relate avibactam AUC, C max or T > 1, 2 or 4 mg/L to change in viable count at 24 h (log cfu/mL). Data from the continuous infusion and dose fractionation experiments was included. The relationship between D24 and AUC, C max , T > 1, T > 2 and T > 4 mg/L for the ceftaroline experiments is shown in Figure 5 . The goodness of fit, as described by R 2 , is shown in Table 3 . AUC or C max showed a better relationship to antibacterial effect (D24) than T > avibactam PK measures. For two of the strains, C max had the best relationship to D24 while for the other strain AUC described the antibacterial effect best. Similar data for the ceftazidime data set are shown in Figure 6 and in Table 3 . For two of the three strains, AUC was best related to D24 and for the last T > 2 mg/L (Table 3) . Hence, across the two data sets, avibactam AUC was best related to D24 in three or six experiments, C max in two of six and T > 2 mg/L MacGowan et al.
in one of six experiments. Only for the E. cloacae strain (AmpC producer) was the same PK measure (AUC) best related to D24 in both data sets. C max or AUC were, however, the avibactam PK measure best related to D24 in five of six data sets.
Discussion
The inhibitor AM-112 showed that once a day dosing was superior to three times a day dosing against an E. coli containing TEM-1 and CTX-M b-lactamases. All these experiments were conducted over a maximum of 24 h dosing. The implication of this early work is that for these inhibitors AUC or C max are likely to be the dominant PD drivers and both agents should be present at the same time for maximum reduction in bacterial load and that strain-to-strain differences may be present. Mushtaq et al. 11 used chequerboard design experiments to show that avibactam in combination with ceftaroline exhibited concentration-related increases in activity (as indicated by reducing MIC values to 2 mg/L) up to 0.5 mg/L avibactam against ESBL-producing Enterobacteriaceae; up to 2 mg/L avibactam against AmpC-producing strains and up to 4 mg/L against KPC producers. Although a very different experiment design, our experiments show similar data with avibactam continuous infusion of >0.5-1.0 mg/L needed for the maximum ceftaroline effect against our CTX-M-producing E. coli strain, >1 mg/L avibactam required for the AmpC-producing Enterobacter strain and >2-4 mg/L for the KPC-producing K. pneumoniae. Our work extends that of Mushtaq et al. 11 by showing that more inhibitor is required to suppress growth over 72 h than 24 h as well as confirming that different b-lactamases will require different amounts of avibactam for maximum inhibition. 
Pharmacodynamics of avibactam plus two cephalosporins
JAC
Both ceftaroline and ceftazidime performed in similar ways with avibactam in these experiments and as far as we know this is the first direct comparison of these agents.
Wiskirchen et al. 12 described the antibacterial effect of ceftaroline 600 mg every 8 h plus avibactam 600 mg every 8 h, at humanized PK profiles, in a neutropenic murine model: reporting a 1-2 log kill at 24 h with a range of Enterobacteriaceae (WT, ESBL, AmpC, KPC producers); however, the experimental design did not allow analysis of the main PK/PD driver for avibactam. Louie et al.
3 studied antibacterial effects of the combination of ceftaroline/avibactam, in an in vitro hollow fibre model against KPC-producing K. pneumoniae, a CTX-M-producing K. pneumoniae and an AmpC-hyperproducing Enterobacter cloacae. In a large set of dose simulations over periods of up to 13 days, the antibacterial effect was studied. Similar to our work, avibactam was given as a continuous infusion with target concentrations of up to 10 mg/L. Over the first 3 days of the simulation of ceftaroline 600 mg every 8 h plus avibactam, continuous infusion !4mg/L was optimal against the KPC-producing strain-this is in very close agreement with our data. In longer-term experiments (i.e. 3-10 days exposure) higher concentrations of avibactam, as continuous infusions, were required to suppress regrowth. Louie et al.
3 also reported the result of dose fractionation experiments comparing similar avibactam 24 h AUC (mgÁh/L) achieved by continuous infusion, every 24, 12 and 8 h, exposures. As with our data in the initial 24 h, no major differences were observed in antibacterial kill kinetics with their different regimens employing both the KPC-and AmpC-producing strains. At later times in these long-term simulations dosing every 8 h and continuous infusion had advantages over the other dosing regimens. The conclusions reached from our data are very similar to Louie et al., accounting for early effect. Using an antibacterial effect measure at 24 h, as is conventional with preclinical PK/PD modelling, we were able to show that avibactam's antibacterial effect was best described in most situations by AUC or C max . The observation that the dominant PK dynamic driver is time dependent is not new: previously Bakker-Woudenberg et al. 13 showed for ceftazidime that short-term outcomes (up to 48 h) were predicted by T > MIC but long term (up to 18 days) by AUC/MIC.
Coleman et al. 4 also employed a hollow fibre model to study the interaction of ceftazidime plus avibactam against eight strains of Enterobacteriaceae with AmpC, ESBL and KPC enzymes (TEM, SHV and CTX-M variants). Ceftazidime was administered by continuous infusion of 8 or 16 mg/L and avibactam given by continuous infusions of 1, 2 or 4 mg/L and single doses to model similar AUC 24 (mgÁh/L) to the continuous infusion experiments. Peak avibactam concentrations ranged from 12 to 60 mg/L. Growth suppression was studied in 16 experiments and single dose and continuous infusion avibactam compared. In 11 of 16 experiments both simulators produced similar results; in four, continuous infusions were best and in one, a single dose. However, three of the four simulations showing superiority of continuous infusion were with a single strain, hence the general applicability of a conclusion based on the work can be questioned as strain to strain variation may be important. Interestingly, this work also indicated that with some strains the bolus injection of avibactam had a superior antibacterial effect to continuous infusion up to 24 h but regrowth occurred after 24 h with a single injection. It is possible to propose, based on these experiments and our own, that the initial reduction of bacterial load is AUC or C max driven up to 24 h but subsequently, in terms of suppression of regrowth related to emergence of resistance, time over threshold is the driver. 3 Our data clearly show that across the three strains tested, time over threshold was not as well related to antibacterial effect measured at 24 h as either AUC or C max .
However, other data do not support this conclusion; e.g. Berkhout et al.
14 using a neutropenic murine pneumonia model of Pseudomonas aeruginosa infection compared 2 h dosing of avibactam to 8 h dosing of avibactam with the same daily dose. E. coli (CTX-M) þ0.6 6 1.0 þ0.9 6 1.5 þ0.6 6 0.7 þ0.6 6 0.7 þ0.9 6 1.5 þ0.5 6 1. MacGowan et al.
Ceftazidime was given by the same dosing regimen in each experiment. The 8 h dosing regimen was less effective than the 2 h regimen leading to the conclusion that time over threshold inhibitor concentration was the driver. However, when bacterial load was related to log of AUC, C max and time > threshold data, the fit was not good and for some strains both AUC and the time > threshold could be related to antibacterial effect. It could be argued that given the short half-life of avibactam in mice then it is highly likely time over threshold would be the dynamic driver. It has been shown for fluoroquinolones, for example, that T > MIC is the PD driver if doses are widely spaced. 15 Alternatively an appropriate conclusion could be that different experimental designs that produce differently distributed data Pharmacodynamics of avibactam plus two cephalosporins JAC will directly impact on the conclusion as to what is the dominant driver. Singh et al. 5 studied the combination of aztreonam and avibactam and showed the T > MIC threshold to be the dominant avibactam PD driver. Comparison with our data is instructive as to the limitations of the T > threshold inhibitor concentration as a PD index. In contrast to our data, Singh et al. conducted very few experiments when T > threshold inhibitor concentration was 0% or 100%. As time > threshold inhibitor concentration is a censored measure it assumes that at the T > threshold 0% there is no or little activity and at 100% there can be no more antibacterial activity after 100% is reached. This is clearly not the case. Hence data sets such as ours with significant numbers of observations at time over threshold inhibitor concentration 0% and 100% will tend to favour AUC or C max over T > threshold, perhaps explaining these discrepancies. These data, and others, indicate the difficulty of determining the dominant PD driver for avibactam. Experimental design is central to this, particularly the number of experiments performed at low and high T > threshold inhibitor concentration exposures, strain differences may play a role, dose frequency and finally whether early (antibacterial kill) or late (emergence of resistance) end points are employed.
Our data, and that of others, indicates AUC and or C max have an important role in the PD of avibactam. As AUC can encompass extremes of exposure when times above or below any threshold are 0% or 100%, it will be useful to explore further how it would be used in translational modelling in humans. AUC-based PK/PD targets might be established by both in vitro and in vivo testing on a wider range of strains and probably higher bacterial inocula as well.
